Our search terms were “NLRP3 inflammasome, multiple sclerosis, experimental autoimmune encephalomyelitis, natural compound, autophagy, small molecular compound, inflammation, mechanism, therapy”. We ...

The NLRP3 inflammasome is implicated in a host ... in preclinical development but being eyed as a possible treatment for multiple sclerosis. Brian Hilberdink, Boehringer Ingelheim's new Head ...

which has just reported phase 1 results with its first two NLRP3 inhibitors, and ZyVersa Therapeutics with preclinical-stage candidate IC 100 that is being considered for multiple sclerosis.

Manuscript Summary Submission Deadline 30 May 2025 | Manuscript Submission Deadline 29 June 2025 | Manuscript Extension Submission Deadline 30 July 2025 ...

A new study suggests that high doses of vitamin D supplements could help reduce disease activity among multiple sclerosis ...

Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...

Previous research has shown that vitamin D deficiency can increase the risk of multiple sclerosis (MS) — and a new study suggests that supplementing it in high doses could help reduce symptoms.

Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review for the regulatory submission of tolebrutinib ...

Multiple Sclerosis: Cell-Catching Implant Helps Identify Successful Treatment in Mice Feb. 18, 2025 — A sponge-like implant in mice helped guide a treatment that slowed or stopped a degenerative ...

Researchers from CHU Nîmes, Université Montpellier, and multiple MS centers in France have found that oral cholecalciferol in ...

Observational studies and two randomized controlled trials consistently suggest that, in general, disease recurrence after ...